Trial reportThe Journal of clinical endocrinology and metabolism2026
Copeptin kinetics in healthy aging.
Trial report in The Journal of clinical endocrinology and metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
contextThe risk for disturbances in water homeostasis-resulting in hypo- or hypernatremia-increases with age. Age-related changes in arginine vasopressin (AVP) kinetics have been suggested, but findings are inconclusive due to challenges in quantifying AVP. Copeptin is a stable surrogate marker for AVP secretion, yet no data on age-related changes of copeptin kinetics are available.
objectiveWe investigated copeptin kinetics in healthy ageing, hypothesizing a reduced within-subject range of copeptin in older individuals.
methodsFor this randomized controlled cross-over trial, 16 healthy older adults aged ≥60 years and 16 healthy younger adults aged 18-30 years were recruited. Participants underwent 1 copeptin stimulation test (infusion of 10 mL/kg of 3% saline in 60 minutes) and 1 copeptin suppression test (ingestion of 20 mL/kg tap water in 60 minutes) in randomized order. During both tests, copeptin was measured at baseline and at 15, 30, 45, 60, and 120 minutes. The primary outcome was the within-subject copeptin range in older adults compared with younger controls.
resultsMedian (interquartile range) age of older adults was 67 (64, 72) years and 26 (23, 28) years in younger controls. In both groups, 50% were female. The within-subject copeptin range in older adults was 12.6 (8.5, 18.7) pmol/L and comparable with that of younger controls with 14.2 (8.5, 16.6) pmol/L (P = .867). While the copeptin response to stimulation was comparable between groups (β = +3.9 [95% CI: -2.9, +10.7; P = .020] pmol·h/L for older adults), older adults exhibited a smaller decrease than younger controls during suppression (β = + .8 [95% CI: +0.3, +1.3; P = .005] pmol·h/L).
conclusionCopeptin kinetics are mostly preserved in healthy older adults, yet the ability to suppress copeptin after hydration is diminished. This may contribute to the higher prevalence of hyponatremia in older individuals and should be considered in future fluid intake guidelines.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.